Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-08-16
2009-10-06
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S009100, C424S009200, C424S130100, C424S139100, C424S141100, C424S150100, C424S178100, C424S234100, C424S236100, C424S239100
Reexamination Certificate
active
07597891
ABSTRACT:
A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment ofC. difficileassociated disease in a human is also provided wherein dimeric or polymeric IgA is modified with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method ofC. difficiletreatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
REFERENCES:
patent: 5190752 (1993-03-01), Moller et al.
patent: 5773000 (1998-06-01), Bostwick et al.
patent: 6162904 (2000-12-01), Mamidi et al.
patent: 6932967 (2005-08-01), Simon
patent: 6967106 (2005-11-01), Simon
patent: 7186410 (2007-03-01), Chtourou et al.
Kelly, C.P. Immune response toClostridium difficileinfection. European Journal of Gastroenterology & Hepatology. vol. 8, No. 11, pp. 1048-1053. 1996.
Mulligan, M.E., et al. Elevated levels of serum immunoglobulins in asymptomatic carriers ofClostridium difficile. Clinical Infectious Diseases, vol. 16, suppl. 4, pp. S238-S244, 1993.
Delacroix, D.L,. et al., “Selective Transport of Polymeric Immunoglobulin A in Bile”, J. Clin Invest., The Anderson Society for Clinical Investigation, Inc., vol. 70, Aug. 1982, pp. 230-241.
Delacroix, D.L., et al., “Changes in Size, Subclass, and Metabolic Properties of Serum Immunoglobulin A in Liver Diseases and in Other Diseases with High Serum Immunaglobulin A”, J. Clin. Invest., The American Society for Clinical Investigation, Inc., vol. 71, Feb. 1993, pp. 358-367.
Gifford Krass Sprinkle Anderson & Citkowski P.C.
Swartz Rodney P.
LandOfFree
Synthesis of human secretory IgA for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of human secretory IgA for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of human secretory IgA for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4108556